Nanoform small is powerful logo Nanoform small is powerful logo
  • Contact Us
  • About Nanoform
    About Nanoform
    • Vision, mission and values
    • Organization
      Board of Directors
      CEO and Management Team
    • Success stories
    • Corporate Responsibility
  • Technology
    Technology
    • CESS®
      STARMAP®
    • Biologics
      Formulations
    • Case studies
  • Services
    Services
    • GMP Manufacturing
  • Corporate Governance
    Corporate Governance
    • Corporate Governance Statements
      General meeting
      Annual General Meeting 2022
      General meetings
    • The Board of Directors
      Board of Directors
      Duties of the Board of Directors
      Authorisations
      Board committees
      Remuneration of the Board
    • CEO and Management Team
      Remuneration
      Audit
      Internal Control and Risk Management
      Code of conduct
    • Articles of Association
      Insider administration
      Disclosure policy
      Transcations of managers
  • Investors
    Investors Investerare Sijoittajat
    • Financial Reports and Presentations
      Press releases
      Subscribe
    • Share and shareholders
      Share information
      Share capital development
      Certified Adviser
      Analyst Coverage
      Ownership structure
      Notifications of major shareholdings
      Manager Transactions
    • IPO 2020
    • Investor calendar
      Contact
    • Finansiella rapporter och presentationer
      Pressmeddelanden
      Prenumerera
    • Aktien och aktieägare
      Aktieinformation
      Aktiekapitalets utveckling
      Certified Adviser
      Analytiker
      Ägarstruktur
      Anmälan om betydande aktieägare
      Transaktioner utförda av personer i ledande ställning
    • Börsnotering
    • Investerarkalender
      Kontakt
    • Taloudelliset raportit ja esitykset
      Tiedotteet
      Tilaaminen
    • Osake ja osakkeeomistajat
      Tiedot osakkeesta
      Osakepääoman kehitys
      Hyväksytty neuvonantaja
      Analyytikot
      Omistusrakenne
      Ilmoitukset merkittävistä osakkeenomistajista
      Johtohenkilöiden liiketoimet
    • Listautuminen
    • Sijoittajakalenteri
      Yhteystiedot
  • Media
    Media
    • Press releases
      News
    • Pharmaceutical events
      Articles & videos
    • Subscribe
      Brochure
    • Contact
  • Careers
  • Contact

Press releases

Regulatory Releases
  • Press Releases
  • All releases
2020
  • 2023
  • 2022
  • 2021
  • 2019
  • 2018
  • All years
All categories
  • Manager Transactions
All languages
  • English
  • Finnish
  • Swedish
Regulatory
December 17, 2020

Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules

Regulatory
November 27, 2020

Nanoform Finland Plc, Interim Report January – September 2020, November 27[th], 2020 at 08:00 a.m. Finnish time

Regulatory
November 27, 2020

Nanoform launches technology for biologics and sets new near-term business target for 2021

Regulatory
October 23, 2020

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees

Regulatory
October 20, 2020

Nanoform initiates GMP campaign for first-in-human trial of nanoformed drug by year end – ahead of schedule

Regulatory
September 2, 2020

Nanoform Finland Plc – Manager’s transactions – Goncalo Andrade

Regulatory
September 2, 2020

Share subscriptions based on Nanoform Finland Plc’s 2/2019 and 1/2020 Stock Option Programs

Regulatory
September 1, 2020

Resolutions of Nanoform Finland Plc’s Extraordinary General Meeting and Board of Directors on September 1, 2020

Regulatory
August 28, 2020

NANOFORM FINLAND PLC, 2020 HALF YEAR FINANCIAL REPORT, 28 AUGUST 2020 AT 8:10 AM EEST

Regulatory
August 6, 2020

Kutsu Nanoform Finland OyJ:n ylimääräiseen yhtiökokoukseen

Regulatory
August 6, 2020

Notice to the extraordinary General Meeting of NANOFORM FINLAND PLC

Regulatory
August 6, 2020

Nanoform convenes EGM to elect Cynthia Schwalm as board member

Regulatory
June 25, 2020

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees

Regulatory
June 10, 2020

Nanoform Finland Plc – Manager’s transactions – Albert Hæggström

Regulatory
June 10, 2020

Nanoform Finland Plc – Manager’s transactions – Edward Hæggström

Regulatory
June 10, 2020

Exercise of over-allotment option in relation to the initial public offering of Nanoform Finland Plc and termination of the stabilization period

Regulatory
June 10, 2020

Nanoform Finland Oyj:n listautumisannin lisäosakeoption toteuttaminen ja vakauttamisajan päättäminen

Regulatory
June 10, 2020

Utnyttjande av övertilldelningsoptionen i noteringen av Nanoform Finland Plc och avbrytande av stabiliseringsperioden

Regulatory
June 9, 2020

Nanoform Finland Plc’s ten largest shareholders after the completion of the Initial Public Offering

Regulatory
June 9, 2020

Nanoform Finland Oyj:n kymmenen suurinta osakkeenomistajaa listautumisannin päättymisen jälkeen

Regulatory
June 9, 2020

De tio största aktieägarna i Nanoform Finland Plc efter genomförandet av noteringen

Regulatory
June 3, 2020

Erbjudandet i samband med noteringen av Nanoform har kraftigt övertecknats och kommer att genomföras som planerat – handel i aktierna förväntas inledas imorgon

Regulatory
June 3, 2020

Nanoformin listautumisanti on huomattavasti ylimerkitty ja listautuminen toteutetaan suunnitellusti – osakkeiden kaupankäynnin odotetaan alkavan huomenna

Regulatory
June 3, 2020

The IPO of Nanoform has been considerably oversubscribed and the listing will be completed as planned – trading in the shares is expected to commence tomorrow

Regulatory
June 2, 2020

The institutional offering of Nanoform has been considerably oversubscribed and therefore the subscription period has been closed

Regulatory
June 2, 2020

Nanoformin Instituutioanti on huomattavasti ylimerkitty ja tämän takia merkintäaika on päätetty

Regulatory
June 2, 2020

Det institutionella erbjudandet i Nanoform är kraftigt övertecknat och teckningsperioden har därmed avslutats

Regulatory
June 1, 2020

Nanoformin Yleisöanti on huomattavasti ylimerkitty ja tämän takia merkintäaika on päätetty

Regulatory
June 1, 2020

Erbjudandet i samband med noteringen av Nanoform är kraftigt övertecknat och teckningsperioden har därmed avslutats

Regulatory
June 1, 2020

Public offering of Nanoform has been considerably oversubscribed and therefore the subscription period has been closed

Regulatory
May 28, 2020

Nanoform Finland Plc har ansökt om upptagande till handel av dess aktier på Nasdaq First North Premier Growth Market Finland och Nasdaq First North Premier Growth Market Sweden

Regulatory
May 28, 2020

Nanoform Finland Oyj on hakenut osakkeidensa listausta Nasdaq First North Premier Growth Market Finlandissa ja Nasdaq First North Premier Growth Market Swedenissä

Regulatory
May 28, 2020

Nanoform Finland Plc has applied for its shares to be listed on Nasdaq First North Premier Growth Market Finland and Nasdaq First North Premier Growth Market Sweden

Regulatory
May 25, 2020

Nanoform offentliggör en fast teckningskurs och publicerar ett prospekt för den planerade parallellnoteringen av dess aktier på Nasdaq First North Premier Growth Market i Finland & Sverige

Regulatory
May 25, 2020

Nanoform julkistaa suunnitellun listautumisantinsa kiinteän merkintähinnan sekä esitteen liittyen kaksoislistautumiseensa Nasdaq First North Premier Growth Market -markkinapaikoille Suomessa ja Ruotsissa

Regulatory
May 25, 2020

Nanoform announces a fixed subscription price and publishes a prospectus for its contemplated IPO and dual listing of its shares on Nasdaq First North Premier Growth Markets in Finland & Sweden

Regulatory
May 11, 2020

Nanoform intends to launch an initial public offering and dual listing on Nasdaq First North Premier Growth Markets in Finland & Sweden

Regulatory
May 11, 2020

Nanoform avser att genomföra ett erbjudande och att parallellnoteras på Nasdaq First North Premier Growth Market i Finland & Sverige

Regulatory
May 11, 2020

Nanoform harkitsee listautumisantia ja kaksoislistautumista Nasdaq First North Premier Growth Market Finland ja Sweden -markkinapaikoille

Contact us

+358 29 370 0150
info@nanoform.com

  • Privacy notice
  • Cookies

Subscribe

Read more about our protection of your personal data.

Nanoform Finland Oyj
Cultivator II, Viikinkaari 4
FI-00790 Helsinki
Finland
Company number: 2730572-8